STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW

Starling Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$6.46+0.03 (+0.47%)

Close on Oct 19, 2026

Market cap: $665.58M
P/E (TTM): –
Dividend yield: –

Starling Oncology, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	503	393	324	252	203	188
Selling, General & Admin	106	108	114	120	83	42
General & Administrative	–	–	–	–	–	0.31
Operating Income	-36	-60	-77	-82	-46	-8.20
Interest Expense	11	7.50	6.78	–	0.32	0.35
Interest & Investment Income	–	–	–	–	–	0.25
Other Non-Operating Income	-25	-4.55	-6.09	82	34	-6.62
Asset Impairment Charges	0	0	17	9.94	0	7.50
Gain (Loss) on Sale of Assets	0	-0.27	0.03	-0.02	0	-0.06
Pretax Income	-61	-65	-83	-0.09	-12	-15
Income Tax Expense	-0.13	0	-0.04	-0.24	-0.67	-0.49
Net Income incl. Noncontrolling Interests	–	–	–	–	–	-8.34
Net Income	-61	-65	-83	0.15	-11	-14
Preferred Dividends	–	–	0	0.06	0	–
Net Income to Common	-50	-53	-68	0.07	-11	–
EPS (Basic)(per share)	-0.54	-0.71	-0.92	0.00	-0.16	-0.24
EPS (Diluted)(per share)	-0.54	-0.71	-0.92	-0.21	-0.16	-0.24
Shares Outstanding (Basic, Weighted)(shares)	92	75	74	73	66	59
Shares Outstanding (Diluted, Weighted)(shares)	92	75	74	81	66	59
EBITDA	-29	-54	-71	-78	-43	-5.02
Net Interest Income	–	–	-6.78	-4.08	-0.32	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -4.4%
Net margin: -6.2%
Return on equity, FY2025: 999.2%

Financial strength

Current ratio: 1.36
Debt to equity: -3.21
Debt to assets: 44.8%
Cash to current liabilities: 43.3%

Valuation

P/E ratio: –
Price to sales: 1.13
Price to book: –
Dividend yield: –